Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ASN001 |
Synonyms | |
Therapy Description |
ASN001 selectively binds to and inhibits steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17), which potentially leads to decreased androgen production and in turn, growth inhibition of androgen-dependent tumor cells (PMID: 29882332). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ASN001 | Hormone - Anti-androgens 54 | ASN001 selectively binds to and inhibits steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17), which potentially leads to decreased androgen production and in turn, growth inhibition of androgen-dependent tumor cells (PMID: 29882332). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02349139 | Phase Ib/II | ASN001 | Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer | Terminated | USA | 0 |